ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

ADHD Medication Tied to Homicidal Thoughts – CCHR Demands Urgent Consumer Alerts

News Source: Citizens Commission on Human Rights

LOS ANGELES, Calif., July 21, 2025 (SEND2PRESS NEWSWIRE) – The mental health industry watchdog Citizens Commission on Human Rights International (CCHR) is calling for sweeping reforms to inform families and patients about hidden, potentially life-threatening side effects linked to widely prescribed Attention Deficit Hyperactivity Disorder (ADHD) drugs. The demand follows alarming new regulatory agency warnings from Australia and Germany about atomoxetine, a “non-stimulant” ADHD medication, which is now linked to homicidal thoughts in both children and adults.

The mounting international warnings about ADHD drugs highlight a failure of informed consent on a massive scale
Image caption: The mounting international warnings about ADHD drugs highlight a failure of informed consent on a massive scale. This is a complete breakdown of a system that should uphold the highest standard of informed consent.

In May, Australia’s Therapeutic Goods Administration (TGA) issued an urgent update to the product information for atomoxetine hydrochloride, warning of the risk of “aggressive behavior including homicidal ideation” in children and adults.[1] A separate alert in June emphasized “severe cases” of “physical assault, or threatening behavior and thoughts of harming others.”[2] The updated product information also says that “aggressive behavior or hostility was more frequently observed in clinical trials among children, adolescents, and adults treated with atomoxetine compared to placebo.”[3]

In February, Germany’s Federal Institute for Drugs and Medical Devices released its own warning, referencing the European Medicines Agency’s Pharmacovigilance Risk Assessment Committee (PRAC), which determined a “possible connection” between atomoxetine and cases of serotonin syndrome—a potentially fatal condition causing toxicity—as well as physical assaults, threatening behavior, and homicidal thoughts.[4]

“The stakes are enormous,” said Jan Eastgate, president of CCHR International. “The Atomoxetine Hydrochloride Market was valued at $1.2 billion last year, and the U.S. ADHD drug market overall has ballooned to $20 billion annually. Yet consumers remain uninformed of the magnitude of these risks.”

New studies confirm that atomoxetine’s risks are a small part of much larger concerns with ADHD drugs:

  • A 2024 study found that patients taking higher doses of ADHD drugs were more than five times as likely to develop psychosis or mania compared to lower-dose patients.[5]
  • A 2023 study found a 23% increase in the risk of heart disease among patients who used ADHD drugs for more than five years.[6]
  • The FDA updated its own black box warnings to state that ADHD stimulants can cause addiction. The FDA’s safety communication about the warning states that this can happen even when taken exactly as prescribed.[7]
  • Renowned Danish physician and researcher Dr. Peter C. Gøtzsche describes short-term harms including tics, twitches, compulsive behaviors, aggression, and suicidal or homicidal ideation.[8]

Despite these known risks, prescriptions continue to soar. Using data from IQVIA, CCHR reports that in 2020 alone, over 6.4 million U.S. adults aged 18–65+ were prescribed ADHD stimulants, including more than 340,000 seniors. In the same year, over 3.1 million children and teens aged 17 and under were prescribed ADHD stimulants—including more than 58,000 children under the age of five, even though these drugs are not FDA-approved for such young children.

CCHR emphasizes that parents are rarely told that ADHD is diagnosed subjectively—there is no objective lab test or scan to substantiate it. A recent study from the University of Copenhagen analyzed 292 randomized controlled trials for adult ADHD and found widespread methodological flaws. Many trials relied on self-diagnosis, online checklists, or untrained staff, and more than half included participants with other psychiatric labels, making the data unreliable.[9]

This echoes a major exposé in 2022 that debunked the “chemical imbalance” myth used for decades to justify antidepressant use—a marketing ploy that convinced millions they had a brain defect requiring pills.

SciTech Daily reported on the Copenhagen findings: “With adult ADHD diagnoses soaring, often driven by online content, the findings raise serious concerns about research reliability and treatment accuracy. If flawed science is shaping how millions are treated, are we getting ADHD all wrong?”

Dr. Allen Frances, former chair of the Diagnostic & Statistical Manual of Mental Disorders (DSM) IV task force, has warned that the DSM contributed to “three false epidemics”—ADHD, autism, and childhood bipolar disorder—by pathologizing normal behaviors. He remains a vocal critic of psychiatry’s expansion into ordinary aspects of childhood and adult life.[10]

The Journal of the Royal Society of Medicine recently concluded, “The real epidemic out there is the epidemic of ADHD diagnosing and prescribing… Lacking proven biological anchoring, syndromal categories are susceptible to cultural trends regarding over-medicalization and societal contagion.”[11]

CCHR says the mounting international warnings about atomoxetine and other ADHD drugs highlight a failure of informed consent on a massive scale. “The idea that a drug prescribed to millions of children and adults could induce homicidal behavior is nothing short of astonishing—yet parents and consumers remain largely in the dark,” said Eastgate. “This is a complete breakdown of the psychiatric-pharmaceutical industry violating informed consent. Regulators, prescribers, and manufacturers must be held accountable for ensuring clear, timely warnings reach every patient and parent before a pill is ever swallowed. Anything less is a betrayal of public trust—and leaves lives needlessly at risk.”

Founded in 1969 by the Church of Scientology and professor of psychiatry, Dr. Thomas Szasz, CCHR is a nonprofit mental health industry watchdog dedicated to investigating and exposing psychiatric violations of human rights.

To learn more, visit: https://www.cchrint.org/2025/07/18/regulators-warn-adhd-drug-can-trigger-homicidal-thoughts-parents-and-consumers-need-to-be-informed/

Sources:

[1] Australian Therapeutic Goods Administration “Product Information safety updates – April 2025,” 22 May 2025, https://www.tga.gov.au/news/safety-updates/product-information-safety-updates-april-2025-0

[2] Australian Therapeutic Goods Administration “Product Information safety updates – May 2025, Product Information safety updates,” 26 June 2025, https://www.tga.gov.au/news/safety-updates/product-information-safety-updates-june-2025

[3] AUSTRALIAN PRODUCT INFORMATION ATOMOXETINE HYDROCHLORIDE CAPSULES

[4] “Atomoxetine: New warnings about serotonin syndrome and homicidal thoughts,” Federal Institute for Drugs and Medical Devices, 7 Feb. 2025, https://www.bfarm.de/SharedDocs/Risikoinformationen/Pharmakovigilanz/EN/RI/2025/RI-atomoxetin.html

[5] https://www.yahoo.com/news/high-doses-adhd-drugs-linked-110000596.html; https://www.nbcboston.com/news/local/adhd-medication-warning/3485513

[6] https://www.cnn.com/2023/11/22/health/adhd-medication-heart-disease-risk-wellness/index.html; https://jamanetwork.com/journals/jamapsychiatry/fullarticle/2811812

[7] “FDA updating warnings to improve safe use of prescription stimulants used to treat ADHD and other conditions,” FDA, 11 May 2023, https://www.fda.gov/media/168066/download

 

[8] https://www.madinamerica.com/2023/08/critical-psychiatry-textbook-chapter-9-part-two/

[9] https://scitechdaily.com/misdiagnosed-millions-why-adhd-science-may-be-leading-us-astray/

[10] Derek Summerfield, “‘Adult ADHD’ and ‘neurodevelopmental disorder’ – a critique of the latest socio-psychiatric ‘epidemic,’” Journal of the Royal Society of Medicine, 22 Jan. 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11755421/

[11] Derek Summerfield, “‘Adult ADHD’ and ‘neurodevelopmental disorder’…,” Journal of the Royal Society of Medicine, https://pmc.ncbi.nlm.nih.gov/articles/PMC11755421/

MULTIMEDIA;

Image link for media: https://www.Send2Press.com/300dpi/25-0721-s2p-cchradhd-300dpi.jpg

Image caption: The mounting international warnings about ADHD drugs highlight a failure of informed consent on a massive scale. This is a complete breakdown of a system that should uphold the highest standard of informed consent.


This press release was issued on behalf of the news source (Citizens Commission on Human Rights), who is solely responsible for its accuracy, by Send2Press Newswire.

To view the original story, visit: https://www.send2press.com/wire/adhd-medication-tied-to-homicidal-thoughts-cchr-demands-urgent-consumer-alerts/

Copr. © 2025 Send2Press® Newswire, Calif., USA. -- REF: S2P STORY ID: S2P127866 FCN24-3B

 

INFORMATION BELOW THIS PAGE, IF ANY, IS UNRELATED TO THIS PRESS RELEASE.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.